Processa Pharmaceuticals, Inc. (PCSA) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
PCSA Revenue Analysis (2013–2024)
As of March 1, 2026, Processa Pharmaceuticals, Inc. (PCSA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, PCSA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $312,480 in 2013.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY). Compare PCSA vs UTHR →
Peer Comparison
Compare PCSA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PCSACurrent | $0 | - | - | - | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-12,051,206 | - |
| 2023 | $0 | - | $0 | - | $-11,457,061 | - |
| 2022 | $0 | - | $0 | - | $-27,525,431 | - |
| 2021 | $0 | - | $0 | - | $-12,133,543 | - |
| 2020 | $0 | - | $-882,062 | - | $-15,136,859 | - |
| 2019 | $0 | - | $-877,897 | - | $-3,935,482 | - |
| 2018 | $0 | - | $-630,092 | - | $-4,524,940 | - |
| 2017 | $0 | -100.0% | $-1,865 | - | $-1,802,433 | - |
| 2016 | $5K | -95.6% | $4K | 72.4% | $-1,921,520 | -38430.4% |
| 2015 | $113K | -43.3% | $-12,451 | -11.0% | $2.7M | 2372.6% |
See PCSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCSA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PCSA vs AGIO
See how PCSA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PCSA's revenue growth accelerating or slowing?
PCSA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is PCSA's long-term revenue growth rate?
Processa Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is PCSA's revenue distributed by segment?
PCSA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.